An interventional study of SEEG RF-TC in Drug-Resistant Epilepsy, sponsored by Beijing Pins Medical Co., Ltd. Not yet recruiting at 17 sites in China. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Beijing Pins Medical Co., Ltd · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Drug Resistant Epilepsy with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Drug Resistant Epilepsy · China.
Among the 27 studies in Drug Resistant Epilepsy with a site in China, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 19 with no phase, reaches primary completion later than 13 of the 17 other live ones, and was the 27th registered.
257 studies on the registry are indexed under Drug Resistant Epilepsy; 108 are open to participants now.
Browse Drug Resistant Epilepsy studies →16 of the 27 studies in Drug Resistant Epilepsy with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75
Xuanwu Hospital, Beijing · Sites in China
Ages 18–60
Xuanwu Hospital, Beijing · Sites in China
Ages 6–60
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
Xuanwu Hospital, Beijing · Sites in China
Ages 14–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 66 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 39 (59%) stop at 75 or younger; 25 take children under 18; 6 take healthy volunteers.
This study: 2 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Median enrollment 30 across the 22 interventional studies, 50 across the 5 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 27 have an industry lead sponsor. The 8 most frequent:
Beijing Pins Medical Co., Ltd is the lead sponsor of 31 studies on the registry; 5 are open to participants now.
Beijing Pins Medical Co., Ltd has 5 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
4 of the studies in Drug Resistant Epilepsy with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07305311Xuanwu Hospital, BeijingCharacterising the Network-Specific Effects of Piriform Cortex Stimulation Via SEEG | 2027-01-08 |
| NCT06832813Xijing HospitalLong Term Efficacy and Safety of TMS Targeting Cerebellum to Treat DRE | 2027-03-27 |
| NCT06557720Xijing HospitalExploring the Characteristics of Epileptogenic Foci in Drug-Resistant Epilepsy Based on Multimodal Imaging Technology | 2027-06-11 |
| NCT07923058Beijing Pins Medical Co., LtdClinical Trial of SEEG for Drug-resistant Epilepsy | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Drug Resistant Epilepsy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial evaluates the safety and efficacy of SEEG recording and functional mapping for patients with drug-resistant epilepsy. It also assesses the safety and therapeutic effectiveness of SEEG-guided radiofrequency ablation for this patient group. The study will collect clinical evidence to support the standardized application of this combined diagnostic and treatment workflow for drug-resistant epilepsy.
Stereoelectroencephalography (SEEG) is a minimally invasive presurgical evaluation modality for epilepsy. Intracranial electrodes are implanted using stereotactic techniques to record intracranial electroencephalographic (EEG) activity and deliver direct electrical stimulation, with the aim of delineating the epileptogenic zone in patients with focal epilepsy. Based on SEEG findings, clinicians can achieve highly precise localization of the epileptogenic zone and tailored surgical planning, or directly utilize SEEG-guided radiofrequency thermocoagulation (SEEG RF-TC) as an independent therapeutic intervention.
This study adopts a single-arm target-value design with a planned enrollment of 99 patients. All enrolled participants will undergo SEEG electrode implantation, followed by continuous SEEG monitoring for EEG recording and comprehensive presurgical evaluation. Eligible patients will then receive SEEG-guided radiofrequency thermocoagulation treatment. The primary efficacy endpoints include the success rate of intracranial EEG signal recording and the therapeutic response rate of thermocoagulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this trial will undergo SEEG electrode implantation followed by SEEG recording and mapping, and will complete SEEG radiofrequency thermocoagulation (RF-TC).
Procedure: SEEG RF-TC
The patient will undergo SEEG-guided radiofrequency thermocoagulation (RF-TC). The procedure includes: electrode implantation, EEG recording, SEEG RF-TC, and electrode extraction.
Also known as: SEEG-guided radiofrequency thermocoagulation
SEEG Recording Success Rate
The proportion of patients achieving successful SEEG recording
Time frame: Within 30 days after implantation of electrodes
RF-TC Efficacy Rate
The proportion of patients achieving successful RF-TC.RF lesion measured on the post-procedural brain MRI.
Time frame: Within 3 days after RF-TC
Electrode Placement Accuracy
co-registering the pre-operative surgical plan and post-op CT，calculate the error between the actual placement position of the electrode and the surgical plan at the skull entry point and the target point.Measuring unit: mm.
Time frame: Within 30 days after implantation of electrodes
Technical success rate of RF-TC
Medical recording
Time frame: During RF-TC operation
Vital signs-body temperature
From medical recording
Time frame: baseline, Perioperative
Vital signs-pulse
From medical recording
Time frame: baseline, Perioperative
Vital signs-respiratory rate
From medical recording
Time frame: baseline, Perioperative
Vital signs-blood pressure
From medical recording
Time frame: baseline, Perioperative
the reduction rate of spike frequency after RF-TC
SEEG recording
Time frame: Periprocedural of RF-TC
Questionnaire of Device Performance Evaluation
a 5-level scale used to evaluate the Device Performance
Time frame: immediately after the procedure/surgery
Seizure reduction rate
Follow up
Time frame: 90±7 days after RF-TC
Mini-Mental State Examination (MMSE) score
Lower score indicates worse cognitive impairment
Time frame: Before and 90±7 days after RF-TC
Quality of life in epilepsy-31 inventory (QOLIE-31) score
For adult; Higher scores correspond to better health-related quality of life
Time frame: Before and 90±7 days after RF-TC
Quality of life in epilepsy for Adolescents (QOLIE-AD-48) score
For Adolescents; Higher scores correspond to better health-related quality of life
Time frame: Before and 90±7 days after RF-TC
child epilepsy questionnnaire-parental form
For children; Higher scores correspond to better health-related quality of life
Time frame: Before and 90±7 days after RF-TC
Incidence of adverse events and serious adverse events
Medical recording
Time frame: through study completion, an average of 5 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.
Of 102 interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 50. This study's planned 8 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Pins Medical Co., Ltd →